|
|
|
|
1 Perspectives on the History and Evolution of Tumor Models |
|
|
3 | (20) |
|
|
|
|
|
Part II Transplantable Syngeneic Rodent Tumors |
|
|
|
2 Murine L1210 and P388 Leukemias |
|
|
23 | (20) |
|
|
|
3 Transplantable Syngeneic Rodent Tumors: Solid Tumors in Mice |
|
|
43 | (36) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 B16 Murine Melanoma: Historical Perspective on the Development of a Solid Tumor Model |
|
|
79 | (20) |
|
|
|
Part III Human Tumor Xenografts |
|
|
|
5 Human Tumor Xenograft Efficacy Models |
|
|
99 | (26) |
|
|
|
|
|
6 Imaging the steps of metastasis at the macro and cellular level with fluorescent proteins in real time |
|
|
125 | (42) |
|
|
|
7 Patient-Derived Tumor Models and Explants |
|
|
167 | (28) |
|
|
|
|
|
8 The Pediatric Preclinical Testing Program |
|
|
195 | (20) |
|
|
|
|
|
9 Imaging Efficacy in Tumor Models |
|
|
215 | (30) |
|
|
|
|
|
|
|
Part IV Carcinogen-Induced Tumors |
|
|
|
10 Mammary Cancer in Rats |
|
|
245 | (14) |
|
|
|
Part V Disease and Target-Specific Models |
|
|
|
11 Animal Models of Melanoma |
|
|
259 | (28) |
|
|
|
|
|
12 Experimental Animal Models for Investigating Renal Cell Carcinoma Pathogenesis and Preclinical Therapeutic Approaches |
|
|
287 | (20) |
|
|
|
13 Animal Models of Mesothelioma |
|
|
307 | (18) |
|
|
|
|
|
|
|
|
|
14 The Use of Mouse Models to Study Leukemia/Lymphoma and Assess Therapeutic Approaches |
|
|
325 | (28) |
|
|
|
15 Spontaneous Companion Animal (Pet) Cancers |
|
|
353 | (24) |
|
|
|
|
|
Part VI Genetically Engineered Mouse Models of Cancer |
|
|
|
16 Genetically Engineered Mouse Models of Pancreatic Ductal Adenocarcinoma |
|
|
377 | (20) |
|
|
|
|
|
17 Transgenic Adenocarcinoma of the Mouse Prostate: A Validated Model for the Identification and Characterization of Molecular Targets and The Evaluation of Therapeutic Agents |
|
|
397 | (26) |
|
|
|
18 The Utility of Transgenic Mouse Models for Cancer Prevention Research |
|
|
423 | (24) |
|
|
|
|
|
|
|
|
|
Part VII Metastasis Models |
|
|
|
19 Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease |
|
|
447 | (52) |
|
|
|
Part VIII Normal Tissue Response Models |
|
|
|
20 Animal Models of Toxicities Caused by Anti-Neoplastic Therapy |
|
|
499 | (22) |
|
|
|
|
|
|
|
21 Bone Marrow as a Critical Normal Tissue that Limits Drug Dose/Exposure in Preclinical Models and the Clinic |
|
|
521 | (32) |
|
|
|
22 Anesthetic Considerations for the Study of Murine Tumor Models |
|
|
553 | (18) |
|
|
|
|
|
|
|
Part IX Experimental Methods and Endpoints |
|
|
|
23 Preclinical Tumor Response End Points |
|
|
571 | (36) |
|
|
|
|
|
607 | (18) |
|
|
|
|
|
625 | (16) |
|
|
|
|
|
|
|
|
|
|
|
26 Transparent Window Models and Intravital Microscopy: Imaging Gene Expression, Physiological Function and Therapeutic Effects in Tumors |
|
|
641 | (40) |
|
|
|
|
|
|
| Index |
|
681 | |
